COMP <GO>
NVST vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Envista Holdings Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NVST 5
— ABBV 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $23.51 (-4.47%) • MKT CAP: $3.95B
roic
5.10%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVST VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVST | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.70% | 70.20% | -15.50 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 5.10% | 29.00% | -23.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.5x | 33.3x | -16.80 | NVST | /valuation <GO> |
| Free Cash Flow Yield | 5.83% | 3.47% | +2.36 | NVST | /fcf-yield <GO> |
| Operating Margin | 7.90% | 24.60% | -16.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 1.70% | 6.90% | -5.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 8.30% | 8.60% | -0.30 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.61 | 5.33 | -3.72 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | NVST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | NVST | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.7 | 72.8 | -25.12 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 1.15 | -0.22 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.2x | 113.1x | -34.90 | NVST | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.95B | $513.86B | -$509.91B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVST REV | ABBV REV | NVST GROSS % | ABBV GROSS % | NVST FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.72B | $61.16B | 54.7% | 70.2% | $230.4M | $17.82B |
| FY 2024 | $2.51B | $56.33B | 54.7% | 70.0% | $302.7M | $17.83B |
| FY 2023 | $2.57B | $54.32B | 44.0% | 44.0% | $160.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVST // BETA 0.93
ABBV // BETA 1.15